Achilles Therapeutics was formed in October 2016 by Syncona Ltd and Cancer Research Technology, with the support of UCLB and the Francis Crick Institute. Steven [...]
BOSTON and LONDON, April 27, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the first patient [...]
Achilles Therapeutics has announced the appointment of Professor Sergio Quezada of the UCL Cancer Institute as Chief Scientific Officer with effect from 6th Apr [...]
Congratulations to Professor Bobby Gaspar of the UCL Great Ormond Street Institute of Child Health who has been named the new CEO of global gene therapy spinout [...]
• PRIME designation granted based on clinical data from ongoing Phase 1/2 trial of AAV-RPGR • AAV-RPGR is the only XLRP treatment in development to be awarded P [...]
Early Clinical Data Support ex vivo Hematopoietic Stem Cell Gene Therapy as a Potentially Promising Treatment Option for X-CGD BOSTON and LONDON, Jan. 29, 2020 [...]
London, 24 January 2020 SmartTarget Ltd, a spinout company of UCL which successfully brought to market image fusion technology allowing accurate targeting of pr [...]
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, has announced Syncona Ltd (Syncona) has made an $ [...]
Abcam plc, a global innovator in life science reagents and tools, and SomaServe Ltd, a Pharma service and specialist reagent business exploiting PolyNaut® Techn [...]
LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation program [...]
